Phase II Multicentered Study of First-Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With the Combination of Carboplatin and Liposomal Doxorubicin
Treatment is planned with carboplatin AUC 5 given IV on day 1 and liposomal doxorubicin 40
mg/m2 given IV on day 1, with treatment repeated every 28 days. Delays in treatment
administration and dose reductions have been planned according to toxicity.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective response rate (complete and partial responses)
Sandro Pignata, M.D., Ph.D
Principal Investigator
National Cancer Institute, Naples
Italy: Ethics Committee
END-1
NCT00401635
November 2002
Name | Location |
---|